Sanofi has reported the latest data from a Phase II clinical trial of a cluster of differentiation 40 ligand (CD40L) monoclonal antibody, frexalimab, in patients with relapsing multiple sclerosis (MS).

The double-blind, randomised, placebo-controlled trial assessed frexalimab in relapsing MS patients who were randomised into a 4:4:1:1 ratio.

They received either 1,200mg intravenous dose every four weeks of the therapy, a 300mg subcutaneous dose every two weeks or a placebo.

Following 12 weeks of treatment, subjects who received a placebo switched to frexalimab, entering the open-label part B portion of the trial, which is presently underway.

According to the trial findings, frexalimab was found to reduce a critical biomarker linked to MS nerve cell damage, confirming the rationale for using this unique mechanism in the Phase III MS trial aimed at delaying disability development.

After one year of treatment, plasma levels of neurofilament light chain (NfL), a biomarker of nerve cell damage that is generally increased in persons with MS, dropped significantly.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Subjects who received high-dose frexalimab saw a decline of 41% in plasma NfL levels from baseline while those in the low-dose frexalimab had a 35% decrease.

Sanofi Neurology Development global head Erik Wallström said: “People with multiple sclerosis need new high-efficacy treatment options that target disability progression, which remains an unmet need.

“These results, alongside the previously reported Phase II efficacy and safety results, further show that frexalimab’s novel mechanism of action has the potential to deliver meaningful improvements for people living with this chronic and debilitating disease.”The company also launched global Phase III trials of frexalimab in relapsing MS and non-relapsing secondary progressive MS and is enrolling patients.

Recently, Sanofi reported positive results from a Phase III trial of Dupixent (dupilumab) in one to 11-year-old children with eosinophilic esophagitis (EoE).